Clinical Trial Update: A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Results from a Phase 1/2 study of CC-220 (iberdomide) as monotherapy and in combination for multiple myeloma, focusing on dose, safety, tolerability and efficac…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• CC-220

Snippet

Sponsor: Celgene | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-03-20